APOA4 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P06727 |
---|---|
Other Accession | A8MSL6 |
Clone Names | 80118122 |
Gene ID | 337 |
---|---|
Other Names | Apolipoprotein A-IV, Apo-AIV, ApoA-IV, Apolipoprotein A4, APOA4 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7591a was selected from the N-term region of human APOA4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | APOA4 |
---|---|
Function | May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons. |
Cellular Location | Secreted. |
Tissue Location | Synthesized primarily in the intestine and secreted in plasma |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The primary translation product of the APOA4 gene is a 396-residue preprotein which after proteolytic processing is secreted into its primary site of synthesis, the intestine, in association with chylomicron particles. Although its precise function is not known, apo A-IV is a potent activator of lecithin-cholesterol acyltransferase in vitro.
References
Chien,K.L., Clin. Chim. Acta 388 (1-2), 78-83 (2008)Bai,H., Acta Cardiol 63 (3), 315-322 (2008)

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.